Xeliri Regimen with Continuous Treatment of Bevacizumab is Well-Tolerated and Effective as Second-Line Chemotherapy in Patients with MCRC

MLA

Junichi Sasaki, et al. “Xeliri Regimen with Continuous Treatment of Bevacizumab Is Well-Tolerated and Effective as Second-Line Chemotherapy in Patients with MCRC.” Annals of Oncology, vol. 24, June 2013, p. iv107. EBSCOhost, https://doi.org/10.1093/annonc/mdt203.251.

APA

Junichi Sasaki, Yutaka J. Kawamura, Toshiki Rikiyama, Fumio Konishi, Shingo Tsujinaka, Koichi Suzuki, Takaharu Kato, & Yuta Muto. (2013). Xeliri Regimen with Continuous Treatment of Bevacizumab is Well-Tolerated and Effective as Second-Line Chemotherapy in Patients with MCRC. Annals of Oncology, 24, iv107. https://doi.org/10.1093/annonc/mdt203.251

Chicago

Junichi Sasaki, Yutaka J. Kawamura, Toshiki Rikiyama, Fumio Konishi, Shingo Tsujinaka, Koichi Suzuki, Takaharu Kato, and Yuta Muto. 2013. “Xeliri Regimen with Continuous Treatment of Bevacizumab Is Well-Tolerated and Effective as Second-Line Chemotherapy in Patients with MCRC.” Annals of Oncology 24 (June): iv107. doi:10.1093/annonc/mdt203.251.